PL362003A1 - Melanocortin receptor ligands - Google Patents

Melanocortin receptor ligands

Info

Publication number
PL362003A1
PL362003A1 PL36200301A PL36200301A PL362003A1 PL 362003 A1 PL362003 A1 PL 362003A1 PL 36200301 A PL36200301 A PL 36200301A PL 36200301 A PL36200301 A PL 36200301A PL 362003 A1 PL362003 A1 PL 362003A1
Authority
PL
Poland
Prior art keywords
receptor ligands
melanocortin receptor
melanocortin
ligands
receptor
Prior art date
Application number
PL36200301A
Other languages
Polish (pl)
Inventor
Frank Hallock Ebetino
Adam W. Mazur
Jeffrey Charles Hayes
Feng Wang
Mark Gregory Solinsky
Anny-Odile Colson
Qishen Lin
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of PL362003A1 publication Critical patent/PL362003A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
PL36200301A 2000-09-27 2001-09-26 Melanocortin receptor ligands PL362003A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23585800P 2000-09-27 2000-09-27
PCT/US2001/030051 WO2002026774A2 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands

Publications (1)

Publication Number Publication Date
PL362003A1 true PL362003A1 (en) 2004-10-18

Family

ID=22887187

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36200301A PL362003A1 (en) 2000-09-27 2001-09-26 Melanocortin receptor ligands

Country Status (19)

Country Link
EP (1) EP1409540A2 (en)
JP (1) JP2004509974A (en)
KR (1) KR100519204B1 (en)
CN (1) CN1571796A (en)
AR (1) AR030806A1 (en)
AU (2) AU9631301A (en)
BR (1) BR0114257A (en)
CA (1) CA2420045A1 (en)
CZ (1) CZ2003788A3 (en)
HU (1) HUP0303085A2 (en)
IL (1) IL154437A0 (en)
MX (1) MXPA03002691A (en)
NO (1) NO20031287L (en)
NZ (1) NZ524190A (en)
PE (1) PE20020447A1 (en)
PL (1) PL362003A1 (en)
RU (1) RU2246501C2 (en)
WO (1) WO2002026774A2 (en)
ZA (1) ZA200301561B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
MXPA06003474A (en) * 2003-09-30 2006-06-05 Novo Nordisk As Melanocortin receptor agonists.
ES2642214T3 (en) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugation of peptides by transglutaminase
RU2309144C2 (en) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Phenyl-containing n-acylamine derivatives, method for production thereof, pharmaceutical composition and uses thereof as anti-inflammatory and analgesic agents
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
KR101482483B1 (en) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
RU2303597C1 (en) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Pharmaceutical composition, method for its preparing and using
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
WO2008107362A2 (en) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Stabiliser and inhibitors of factor vii
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
EA020959B1 (en) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Melanocortin receptor-specific peptides
ES2726946T3 (en) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Benzosulfonamide derivatives, compositions thereof and their use in the prevention of cancer cell metastasis
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
JP2013510881A (en) * 2009-11-16 2013-03-28 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Method for the synthesis of Ac-Arg-cyclo (Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) -NH2
EA021897B1 (en) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Melanocortin-1 receptor-specific cyclic peptides
BR112012011780A2 (en) 2009-11-23 2019-09-24 Palatin Technologies, Inc linear peptide, pharmaceutical composition, method for treating a melanocortin receptor mediated disease, indication, condition or syndrome in a human or non-human mammal and method for treating a condition responsive to changes in melanocortin receptor function in a human or non-human mammal
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2015175558A2 (en) 2014-05-12 2015-11-19 Capacitor Sciences Incorporated Energy storage device and method of production thereof
US10340082B2 (en) 2015-05-12 2019-07-02 Capacitor Sciences Incorporated Capacitor and method of production thereof
US10347423B2 (en) 2014-05-12 2019-07-09 Capacitor Sciences Incorporated Solid multilayer structure as semiproduct for meta-capacitor
CA2965870C (en) 2014-11-04 2023-01-17 Capacitor Sciences Incorporated Energy storage devices and methods of production thereof
KR20170118764A (en) 2015-02-26 2017-10-25 캐패시터 사이언시스 인코포레이티드 Self-recovery capacitors and methods for their production
US9932358B2 (en) 2015-05-21 2018-04-03 Capacitor Science Incorporated Energy storage molecular material, crystal dielectric layer and capacitor
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor
US10305295B2 (en) 2016-02-12 2019-05-28 Capacitor Sciences Incorporated Energy storage cell, capacitive energy storage module, and capacitive energy storage system
US10153087B2 (en) 2016-04-04 2018-12-11 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US9978517B2 (en) 2016-04-04 2018-05-22 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US10395841B2 (en) 2016-12-02 2019-08-27 Capacitor Sciences Incorporated Multilayered electrode and film energy storage device
CN106966927B (en) * 2017-04-13 2018-10-09 菲立化学工程（上海）有限公司 A kind of synthetic method of anti-AIDS drug centre diazo ketone and chlorine ketone
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2119496C1 (en) * 1992-04-14 1998-09-27 Научно-исследовательский институт фармакологии Российской академии медицинских наук Derivatives of n-acylprolyldipeptides
RU2141483C1 (en) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Peptide derivatives or their pharmaceutically acceptable salts, method of their synthesis, use and pharmaceutical composition
US6350430B1 (en) * 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
DK1165613T3 (en) * 1999-03-29 2008-08-25 Procter & Gamble Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction

Also Published As

Publication number Publication date
CN1571796A (en) 2005-01-26
BR0114257A (en) 2003-07-01
MXPA03002691A (en) 2003-06-06
JP2004509974A (en) 2004-04-02
HUP0303085A2 (en) 2003-12-29
RU2246501C2 (en) 2005-02-20
IL154437A0 (en) 2003-09-17
KR100519204B1 (en) 2005-10-06
KR20030061814A (en) 2003-07-22
NZ524190A (en) 2004-09-24
NO20031287D0 (en) 2003-03-20
CZ2003788A3 (en) 2003-08-13
AU9631301A (en) 2002-04-08
AR030806A1 (en) 2003-09-03
PE20020447A1 (en) 2002-07-02
CA2420045A1 (en) 2002-04-04
NO20031287L (en) 2003-03-20
EP1409540A2 (en) 2004-04-21
ZA200301561B (en) 2004-03-10
WO2002026774A2 (en) 2002-04-04
AU2001296313B2 (en) 2005-06-02
WO2002026774A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
IL154437A0 (en) Melanocortin receptor ligands
IL152781A0 (en) Melanocortin receptor ligands
IL157969A0 (en) Melanocortin receptor ligands
IL145406A0 (en) Melanocortin receptor ligands
AU8066701A (en) Capsaicin receptor ligands
GB9808229D0 (en) Melanocortin receptor ligands
AU6497701A (en) Melanocortin receptor agonists
PL376702A1 (en) Melanocortin receptor ligands
IL164766A0 (en) Melanocortin receptor ligands
GB0302803D0 (en) Not available
GB0012054D0 (en) Ligands
GB0000474D0 (en) Receptor
AU1252102A (en) Receptor
GB0012121D0 (en) Bracket
SG89389A1 (en) Heat-transpiration mat
GB0017591D0 (en) Pipe-chamfering means
GB0014761D0 (en) Receptor
GB0009269D0 (en) Receptor
GB0031096D0 (en) Receptor
PL111717U1 (en) Bracket
GB0025008D0 (en) Bracket
GB0010385D0 (en) Bracket
AU142079S (en) Retaining bracket
GB0022798D0 (en) Mat
GB0018923D0 (en) Anti-oligomer mat

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)